Clinical trials: Nutritional Deficiencies
Cerebral Amyloid Angiopathy
Study Evaluating the Safety,Tolerability and Efficacy of PF-04360365 in Adults With Probable Cerebral Amyloid Angiopathy
Cerebral Amyloid Angiopathy (CAA) is a condition caused by the build-up of a protein called amyloid, predominantly Aβ40, within the walls of brain blood vessels, especially those blood vessels in the occipital lobe of the brain.
- Trial name
- NCT01821118
- Testing
- Ponezumab
- Where
- 13 sites in United States, Canada and 3 more
- Volunteers
- 36 people
- Sponsor
- Pfizer
AL Amyloidosis
A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES)
AL (or light chain) amyloidosis begins in the bone marrow where abnormal proteins misfold and create free light chains that cannot be broken down.
- Trial name
- NCT04512235
- Testing
- CAEL-101, cyclophosphamide, bortezomib, and dexamethasone (CyBorD) regimen
- Where
- 110 sites in United States, Australia and 17 more
- Volunteers
- 281 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
ALS, ALS (Amyotrophic Lateral Sclerosis)
Systems Biology of Amyotrophic Lateral Sclerosis (ALS)
The goal of this observational study is to identify molecular features in multiple clinical samples and/or the patient environment that are associated with ALS.
- Trial name
- NCT07007390
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Viome
Amyotrophic Lateral Sclerosis
Study of Ozanezumab (GSK1223249) Versus Placebo in the Treatment of Amyotrophic Lateral Sclerosis
This is a 48-week, randomised, multi-centre, double-blind, placebo-controlled, parallel group investigation of the efficacy and safety of intravenous (IV) ozanezumab (GSK1223249) compared to placebo in subjects with Amyotrophic…
- Trial name
- NCT01753076
- Testing
- Ozanezumab
- Where
- 35 sites in United States, Australia and 9 more
- Volunteers
- 304 people
- Sponsor
- GlaxoSmithKline
Child Nutrition Disorders, Child Malnutrition
ESj- Powder Complete T&A Study
The goal of this study is to gather data on the tolerance and acceptability of a new ONS (ESj-powder complete) in children currently taking ONS.
- Trial name
- ESj (NCT04488718)
- Testing
- EnergieShake® Junior Powder Complete
- Where
- 3 sites in United Kingdom
- Volunteers
- 18 people
- Sponsor
- Anaiah Healthcare Pvt Ltd
Amyotrophic Lateral Sclerosis
Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ZYIL1 in Patients With Amyotrophic Lateral Sclerosis
ZYIL1 is expected to show benefit in patients with Amyotrophic Lateral Sclerosis (ALS). The present study aims to determine the safety, tolerability, pharmacokinetics, and pharmacodynamics of ZYIL1 when administered to subjects…
- Trial name
- NCT05981040
- Testing
- ZYIL1 capsules 25 mg and ZYIL1 capsules 50 mg
- Where
- 7 sites in India
- Volunteers
- 24 people
- Sponsor
- Zydus Lifesciences Limited
Amyotrophic Lateral Sclerosis
Study to Investigate the Efficacy and Safety of FAB122 (Daily Oral Edaravone) in Patients With Amyotrophic Lateral Sclerosis
Multicenter, multinational, double-blind, randomized (2:1), placebo-controlled Phase III study to investigate the efficacy and safety of 100 mg FAB122 once daily as oral formulation in ALS patients.
- Trial name
- ADORE (NCT05178810)
- Testing
- FAB122
- Where
- 38 sites in Belgium, France and 9 more
- Volunteers
- 313 people
- Sponsor
- Ferrer Internacional S.A.
ALS, Amyotrophic Lateral Sclerosis
Intermediate Expanded Access Protocol CNMAu8.EAP04
An Intermediate Expanded Access Protocol (EAP) with CNM-Au8 for Amyotrophic Lateral Sclerosis for NIH Grant RFA-NS-23-012
- Conditions
- ALS, Amyotrophic Lateral Sclerosis, PALS
- Trial name
- NCT06408727
- Testing
- CNM-Au8
- Where
- 8 sites in United States
- Sponsor
- Clene Nanomedicine
Alzheimer Disease
Safety Study of AADvac1, a Tau Peptide-KLH-Conjugate Active Vaccine to Treat Alzheimer's Disease
This first-time-in-man study is mainly designed to assess the safety and tolerability of AADvac1 in the treatment of Alzheimer's disease.
- Trial name
- NCT01850238
- Testing
- AADvac1
- Where
- 3 sites in Austria
- Volunteers
- 30 people
- Sponsor
- Axon Neuroscience SE
Rotator Cuff Tear Arthropathy, Osteoporosis
COMPREHENSIVE® REVERSE SHOULDER Mini BasePlate
Evaluate Survivorship for the Biomet® Comprehensive® Reverse Shoulder Mini Baseplate.
- Conditions
- Rotator Cuff Tear Arthropathy, Osteoporosis, Osteomalacia, Joint; Destruction, Sacroiliac
- Trial name
- NCT02084693
- Testing
- COMPREHENSIVE
- Where
- 5 sites in South Korea
- Volunteers
- 100 people
- Sponsor
- Zimmer Biomet
Amyotrophic Lateral Sclerosis
A 6-Month Extension Study to Assess the Long-Term Safety of Engensis in Amyotrophic Lateral Sclerosis
The purpose of this study is to evaluate the long-term safety of intramuscular administration of Engensis in Participants with Amyotrophic Lateral Sclerosis who were previously randomized, received treatment, and completed the…
- Trial name
- REViVALS-1B (NCT05176093)
- Testing
- Engensis
- Where
- 2 sites in United States, South Korea
- Volunteers
- 8 people
- Sponsor
- Helixmith Co., Ltd.
Malnutrition
The Nutritional Health for the Elderly Reference Centre Study (NHERC Study)
Elderly are at greater risk of dietary insufficiency due to age-related increases in nutrient requirements concomitant with a reduction in energy requirements, decreases in appetite and energy intake.
- Trial name
- NHERC (NCT03240952)
- Where
- 4 sites in Singapore
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Abbott Nutrition
ALS, Amyotrophic Lateral Sclerosis
Clinical Trial - Analyzing Participation Experiences Of Amyotrophic Lateral Sclerosis Patients
Clinical trial participation has always been substantially skewed toward certain demographic groups. However, there has been little study on whether trial qualities impact participation in either a positive or negative way.
- Trial name
- NCT05423678
- Volunteers
- 500 people
- Sponsor
- Power Life Sciences Inc.
Malnutrition
Acceptability and Tolerance Study of New Oral Nutritional Supplement PRAGUE
Tolerance and Acceptability of new oral nutritional supplement - AYMES PRAGUE
- Trial name
- NCT02831647
- Testing
- AYMES PRAGUE
- Volunteers
- 20 people
- Sponsor
- Aymes International Limited
Malnutrition
Nutrition-Focused Quality Improvement Program (QIP) Among Community Dwelling Malnourished Patients
This study aims to assess the malnutrition prevalence of Colombian community-dwelling adults and evaluate the feasibility of a nutrition-focused QIP implemented in a Colombian ambulatory care facility on healthcare utilization.
- Trial name
- NCT04042987
- Where
- Colombia
- Volunteers
- 1,325 people
- Sponsor
- Abbott Nutrition
Iron Deficiency, Anaemia in Children
Multi-center Trial of Ferric Derisomaltose in Children 0 to <18 Years of Age With Iron Deficiency Anemia
Several clinical trials have been reported for ferric derisomaltose where it has been shown to be well tolerated and to improve markers of IDA.
- Trial name
- NCT05179226
- Testing
- Ferric Derisomaltose
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Pharmacosmos A/S
Malnutrition, Malabsorption
High Energy High Protein Peptide Feed Study
Oral nutritional supplements and enteral tube feeds are commonly used to meet the nutritional requirements of patients with disease-related malnutrition, or who require medical nutrition support for other reasons.
- Trial name
- NCT03140371
- Testing
- High energy high protein peptide feed study
- Where
- 10 sites in United Kingdom
- Volunteers
- 20 people
- Sponsor
- Nutricia UK Ltd
Iron Deficiency Anemia
Efficacy Study of Intravenous Iron Preparation to Iron Deficiency Anemia
The purpose of this study is to confirm the non-inferiority of Z-213 compared to Saccharated Ferric Oxide using the maximum change in Hb from baseline over 12 weeks in patients with Iron-deficiency Anemia (IDA)
- Trial name
- NCT02731534
- Testing
- Z-213, Saccharated Ferric Oxide
- Where
- Japan
- Volunteers
- 238 people
- Sponsor
- Zeria Pharmaceutical
Malnutrition
Nutrition Intervention in Older Adults at Risk of Malnutrition
Thailand is one of the fastest aging countries and older adults are at greater risk of having inadequate nutrient intake and malnutrition (undernutrition).
- Trial name
- NCT05682781
- Testing
- Oral Nutritional Supplement, Dietary Counseling
- Where
- 2 sites in Thailand
- Volunteers
- 196 people
- Sponsor
- Abbott Nutrition
Immunoglobulin Light Chain (AL) Amyloidosis
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Immunoglobulin Light Chain (AL) Amyloidosis Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion
Immunoglobulin light chain (AL) amyloidosis is the most common form of systemic amyloidosis. AL amyloidosis has many root causes and is characterized by the overproduction of AL that are secreted by clonal bone marrow plasma…
- Trial name
- NCT06158854
- Testing
- ABBV-383 (Etentamig)
- Where
- 23 sites in United States, Australia and 4 more
- Volunteers
- 76 people
- Sponsor
- AbbVie